CRISPR Therapeutics (CRSP) Financials

$38.95 +0.14 (+0.36%)

Closing price 04:00 PM Eastern

Extended Trading

$38.44 -0.52 (-1.32%)

As of 07:59 PM Eastern

Annual Income Statements for CRISPR Therapeutics

This table shows CRISPR Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-26	-23	-68	-165	67	-349	373	-650	-154	-366
Consolidated Net Income / (Loss)	-26	-23	-68	-165	67	-349	378	-650	-154	-366
Net Income / (Loss) Continuing Operations	-26	-23	-68	-165	67	-349	378	-650	-154	-366
Total Pre-Tax Income	-26	-23	-67	-164	67	-348	380	-651	-151	-363
Total Operating Income	-26	-68	-65	-159	47	-354	374	-673	-223	-467
Total Gross Profit	0.25	5.16	41	3.12	290	0.72	915	1.20	371	37
Total Revenue	0.25	5.16	41	3.12	290	0.72	915	1.20	371	37
Operating Revenue	0.25	5.16	41	3.12	290	0.72	915	1.20	371	37
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	26	73	106	162	243	355	541	674	594	504
Selling, General & Admin Expense	13	31	36	48	63	86	100	102	76	73
Research & Development Expense	13	42	70	114	179	221	341	462	387	321
Other Operating Expenses / (Income)	-	-	-	-	-	48	101	110	130	110
Total Other Income / (Expense), net	-0.09	45	-1.96	-5.49	21	6.38	6.00	23	72	104
Other Income / (Expense), net	0.02	79	-0.20	-1.21	26	6.38	6.00	23	72	104
Income Tax Expense	0.01	0.48	1.75	0.55	0.45	0.81	1.87	-0.33	2.89	3.59
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.01	0.02	-0.04	0.02	-0.02	-0.04	4.98	0.08	-0.07	0.07
Basic Earnings per Share	($5.06)	($1.89)	($1.71)	($3.44)	$1.23	($5.29)	$4.97	($8.36)	($1.94)	($4.34)
Weighted Average Basic Shares Outstanding	5.04M	12.26M	40.06M	47.96M	54.39M	65.95M	75.95M	77.75M	79.22M	84.36M
Diluted Earnings per Share	($5.06)	($1.89)	($1.71)	($3.44)	$1.17	($5.29)	$4.70	($8.36)	($1.94)	($4.34)
Weighted Average Diluted Shares Outstanding	5.04M	12.26M	40.06M	47.96M	56.93M	65.95M	80.39M	77.75M	79.22M	84.36M
Weighted Average Basic & Diluted Shares Outstanding	5.04M	12.26M	40.06M	47.96M	60.85M	75.43M	77.07M	78.65M	80.28M	85.77M

This table shows CRISPR Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-176	-105	-53	-78	-112	89	-120	-126	-86	-34
Consolidated Net Income / (Loss)	-175	-111	-53	-78	-112	89	-117	-126	-86	-37
Net Income / (Loss) Continuing Operations	-175	-111	-53	-78	-112	89	-117	-126	-86	-37
Total Pre-Tax Income	-175	-120	-52	-77	-112	90	-116	-125	-85	-37
Total Operating Income	-182	-132	-64	-95	-132	70	-141	-151	-110	-65
Total Gross Profit	0.09	0.01	100	70	0.00	201	0.50	0.52	0.60	36
Total Revenue	0.09	0.01	100	70	0.00	201	0.50	0.52	0.60	36
Operating Revenue	0.09	0.01	100	70	0.00	201	0.50	0.52	0.60	36
Total Operating Expenses	182	132	164	165	132	132	141	152	111	100
Selling, General & Admin Expense	27	21	22	19	18	16	18	19	17	18
Research & Development Expense	117	104	100	102	91	95	76	80	82	82
Total Other Income / (Expense), net	7.26	11	13	18	21	20	25	26	25	28
Other Income / (Expense), net	7.26	11	13	18	21	20	25	26	25	28
Income Tax Expense	-0.58	-9.48	1.32	0.92	0.41	0.23	0.72	1.29	0.88	0.70
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	1.92	-5.32	-0.03	-0.03	0.05	-0.06	3.47	-0.00	-0.08	-3.31
Basic Earnings per Share	($2.24)	($1.40)	($0.67)	($0.98)	($1.41)	$1.12	($1.43)	($1.49)	($1.01)	($0.41)
Weighted Average Basic Shares Outstanding	78.02M	77.75M	78.68M	79.09M	79.41M	79.22M	81.79M	84.92M	85.23M	84.36M
Diluted Earnings per Share	($2.24)	($1.40)	($0.67)	($0.98)	($1.41)	$1.12	($1.43)	($1.49)	($1.01)	($0.41)
Weighted Average Diluted Shares Outstanding	78.02M	77.75M	78.68M	79.09M	79.41M	79.22M	81.79M	84.92M	85.23M	84.36M
Weighted Average Basic & Diluted Shares Outstanding	78.29M	78.65M	78.94M	79.41M	79.43M	80.28M	84.92M	85.17M	85.35M	85.77M

This table details how cash moves in and out of CRISPR Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	155	162	-76	217	489	237	-246	-716	177	-91
Net Cash From Operating Activities	59	-53	-70	-96	57	-238	539	-496	-260	-143
Net Cash From Continuing Operating Activities	59	-53	-70	-96	57	-238	539	-496	-260	-143
Net Income / (Loss) Continuing Operations	-26	-23	-68	-165	67	-349	378	-650	-154	-366
Consolidated Net Income / (Loss)	-26	-23	-68	-165	67	-349	378	-650	-154	-366
Depreciation Expense	0.13	0.93	3.02	3.52	4.73	9.18	18	24	20	19
Non-Cash Adjustments To Reconcile Net Income	3.11	-35	21	55	34	68	116	110	67	48
Changes in Operating Assets and Liabilities, net	82	4.23	-25	11	-48	33	27	20	-194	156
Net Cash From Investing Activities	-1.15	32	-8.31	-2.77	1.33	-541	-1,035	-259	375	-280
Net Cash From Continuing Investing Activities	-1.15	32	-8.31	-2.77	1.33	-541	-1,035	-259	375	-280
Purchase of Property, Plant & Equipment	-1.15	-3.02	-7.81	-2.77	-6.68	-18	-82	-37	-9.47	-1.90
Acquisitions	-	-0.10	-	-	8.01	-	0.00	0.00	-2.50	0.00
Purchase of Investments	-	-	-0.50	0.00	0.00	-594	-1,509	-1,418	-1,066	-1,486
Sale and/or Maturity of Investments	-	-	-	0.00	0.00	71	556	1,196	1,453	1,208
Net Cash From Financing Activities	97	183	2.61	316	431	1,016	251	39	63	332
Net Cash From Continuing Financing Activities	97	183	2.61	316	431	1,016	251	39	63	332
Issuance of Common Equity	-	89	-	316	431	1,016	251	39	63	332
Effect of Exchange Rate Changes	0.01	-	-	-	0.02	0.04	-0.01	-0.08	0.07	-0.02

This table details how cash moves in and out of CRISPR Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-2.74	-286	132	100	83	-139	318	-223	-259	73
Net Cash From Operating Activities	-105	-113	8.80	-133	-40	-96	110	-96	-107	-50
Net Cash From Continuing Operating Activities	-105	-113	8.80	-133	-40	-96	110	-96	-107	-50
Net Income / (Loss) Continuing Operations	-175	-111	-53	-78	-112	89	-117	-126	-86	-37
Consolidated Net Income / (Loss)	-175	-111	-53	-78	-112	89	-117	-126	-86	-37
Depreciation Expense	5.02	5.85	5.05	4.96	4.93	4.90	4.83	4.85	4.74	4.84
Non-Cash Adjustments To Reconcile Net Income	27	23	20	19	15	14	11	15	15	6.79
Changes in Operating Assets and Liabilities, net	37	-32	37	-79	53	-204	210	10	-40	-24
Net Cash From Investing Activities	87	-176	118	217	121	-81	-98	-127	-162	106
Net Cash From Continuing Investing Activities	87	-176	118	217	121	-81	-98	-127	-162	106
Purchase of Property, Plant & Equipment	-6.02	-6.19	-3.06	-3.56	-2.12	-0.74	-0.72	-0.71	-0.22	-0.25
Purchase of Investments	-326	-494	-266	-187	-245	-368	-334	-476	-409	-267
Sale and/or Maturity of Investments	420	325	387	409	370	287	237	350	248	373
Net Cash From Financing Activities	15	2.48	5.40	17	1.56	39	306	-0.47	9.64	17
Net Cash From Continuing Financing Activities	15	2.48	5.40	17	1.56	39	306	-0.47	9.64	17
Issuance of Common Equity	15	2.48	5.40	17	1.56	39	306	-0.47	9.64	17
Effect of Exchange Rate Changes	-0.10	0.12	0.03	0.03	-0.05	0.06	-0.01	0.00	0.08	-0.09

This table presents CRISPR Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	159	345	271	489	1,067	1,828	2,752	2,243	2,230	2,242
Total Current Assets	157	320	248	466	988	1,717	2,418	1,853	1,908	1,937
Cash & Equivalents	156	316	240	457	944	1,169	923	212	389	298
Short-Term Investments	-	-	-	-	0.00	522	1,456	1,603	1,304	1,606
Accounts Receivable	0.34	3.16	2.63	0.09	0.10	0.14	0.31	0.00	200	25
Prepaid Expenses	0.54	1.51	6.00	9.66	44	26	38	38	14	8.31
Plant, Property, & Equipment, net	1.33	21	19	19	31	42	138	164	152	134
Total Noncurrent Assets	1.26	3.75	4.10	4.12	48	69	197	226	170	171
Long-Term Investments	-	-	-	-	-	-	0.00	53	1.97	0.00
Intangible Assets	0.45	0.40	0.34	0.29	0.24	0.18	0.13	0.07	0.02	0.00
Other Noncurrent Operating Assets	0.10	0.20	0.61	3.83	48	69	197	173	168	171
Total Liabilities & Shareholders' Equity	159	345	271	489	1,067	1,828	2,752	2,243	2,230	2,242
Total Liabilities	124	112	84	97	127	164	352	368	347	310
Total Current Liabilities	10	22	15	28	57	94	120	121	109	88
Accounts Payable	1.58	4.57	1.64	5.07	5.94	9.09	15	27	38	15
Accrued Expenses	8.43	16	11	21	30	54	91	78	45	41
Current Deferred Revenue	0.00	1.03	1.03	1.30	0.96	2.34	1.01	0.00	4.11	3.85
Current Deferred & Payable Income Tax Liabilities	0.08	0.02	0.35	0.40	0.58	10	0.72	0.14	0.44	0.45
Other Current Liabilities	0.06	0.06	0.14	0.12	19	19	12	16	21	28
Total Noncurrent Liabilities	114	90	69	69	70	69	233	246	238	222
Noncurrent Deferred Revenue	75	90	69	69	12	12	12	12	14	12
Other Noncurrent Operating Liabilities	0.28	0.19	0.31	0.24	58	58	220	234	224	210
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-29	233	188	392	939	1,664	2,399	1,875	1,883	1,932
Total Preferred & Common Equity	-29	233	188	392	939	1,664	2,399	1,875	1,883	1,932
Total Common Equity	-29	233	188	392	939	1,664	2,399	1,875	1,883	1,932
Common Stock	4.82	290	313	684	1,164	2,238	2,601	2,737	2,881	3,296
Retained Earnings	-34	-57	-125	-292	-225	-574	-196	-846	-1,000	-1,366
Treasury Stock	0.00	0.00	0.00	-0.06	-0.06	-0.06	-0.06	-0.06	-0.06	-0.06
Accumulated Other Comprehensive Income / (Loss)	-0.01	-0.03	0.01	-0.01	0.01	-0.08	-5.07	-16	1.91	1.84

This table presents CRISPR Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	2,353	2,244	2,197	2,087	2,439	2,340	2,256
Total Current Assets	1,933	1,908	1,860	1,761	2,120	2,010	1,944
Cash & Equivalents	494	344	445	528	707	484	226
Short-Term Investments	1,402	1,539	1,323	1,212	1,401	1,517	1,710
Accounts Receivable	0.05	0.00	70	0.00	0.00	0.00	0.00
Prepaid Expenses	37	25	21	21	11	8.79	8.25
Plant, Property, & Equipment, net	166	162	159	156	147	143	139
Total Noncurrent Assets	255	174	178	170	172	186	174
Long-Term Investments	77	6.32	4.90	0.00	0.00	11	0.00
Intangible Assets	0.08	0.06	0.04	0.03	0.00	0.00	0.00
Other Noncurrent Operating Assets	177	168	173	170	172	175	174
Total Liabilities & Shareholders' Equity	2,353	2,244	2,197	2,087	2,439	2,340	2,256
Total Liabilities	399	389	381	359	355	359	316
Total Current Liabilities	151	147	133	111	119	128	90
Accounts Payable	32	45	28	26	16	9.45	16
Accrued Expenses	103	86	90	66	76	92	47
Current Deferred Revenue	0.00	0.00	0.00	3.50	4.07	4.76	4.48
Current Deferred & Payable Income Tax Liabilities	4.27	0.27	0.56	0.18	1.21	0.45	0.84
Other Current Liabilities	12	16	15	15	21	21	22
Total Noncurrent Liabilities	249	243	248	248	236	231	227
Noncurrent Deferred Revenue	12	12	12	16	14	13	12
Other Noncurrent Operating Liabilities	236	230	236	232	223	218	214
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,954	1,855	1,816	1,728	2,084	1,981	1,940
Total Preferred & Common Equity	1,954	1,855	1,816	1,728	2,084	1,981	1,940
Total Common Equity	1,954	1,855	1,816	1,728	2,084	1,981	1,940
Common Stock	2,712	2,764	2,802	2,824	3,202	3,227	3,258
Retained Earnings	-736	-899	-977	-1,089	-1,116	-1,243	-1,329
Treasury Stock	-0.06	-0.06	-0.06	-0.06	-0.06	-0.06	-0.06
Accumulated Other Comprehensive Income / (Loss)	-22	-9.39	-8.91	-6.80	-1.55	-2.88	11

This table displays calculated financial ratios and metrics derived from CRISPR Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	1,990.69%	693.90%	-92.38%	9,169.85%	-99.75%	127,154.94%	-99.87%	30,885.48%	-89.95%
EBITDA Growth	-274.89%	144.19%	-646.75%	-153.37%	149.48%	-537.27%	217.30%	-257.57%	79.10%	-162.37%
EBIT Growth	-274.66%	140.38%	-724.59%	-146.98%	145.44%	-578.28%	209.04%	-271.40%	76.83%	-140.62%
NOPAT Growth	-288.25%	-164.80%	5.11%	-145.86%	141.73%	-634.38%	249.81%	-226.78%	66.94%	-109.66%
Net Income Growth	-87.04%	10.17%	-194.62%	-141.35%	140.52%	-621.80%	208.25%	-272.16%	76.37%	-138.43%
EPS Growth	-356.85%	62.65%	9.52%	-101.17%	134.01%	-552.14%	188.85%	-277.87%	76.79%	-123.71%
Operating Cash Flow Growth	1,339.89%	-188.95%	-32.60%	-37.30%	158.89%	-520.57%	326.11%	-191.98%	47.48%	45.17%
Free Cash Flow Firm Growth	0.00%	-169.00%	-69.66%	-34.06%	86.57%	-1,554.72%	243.70%	-240.78%	26.65%	50.07%
Invested Capital Growth	0.00%	-3.49%	35.82%	-17.02%	93.26%	-500.53%	177.90%	-65.42%	2,561.61%	-84.90%
Revenue Q/Q Growth	0.00%	0.00%	272.16%	-91.16%	36.16%	-99.07%	1.39%	-91.50%	118.35%	-81.60%
EBITDA Q/Q Growth	0.00%	0.00%	-525.40%	-43.15%	60,445.31%	-67.53%	-7.58%	3.55%	61.46%	-58.14%
EBIT Q/Q Growth	0.00%	0.00%	-418.14%	-41.98%	1,870.63%	-65.49%	-8.73%	3.48%	58.17%	-53.36%
NOPAT Q/Q Growth	0.00%	0.00%	28.90%	-40.98%	800.32%	-50.38%	-8.80%	2.06%	47.47%	-40.37%
Net Income Q/Q Growth	0.00%	0.00%	-32.99%	-40.71%	693.03%	-65.12%	-8.31%	4.51%	56.55%	-52.86%
EPS Q/Q Growth	0.00%	0.00%	-144.53%	-37.60%	348.94%	-72.88%	-0.84%	1.88%	56.50%	-54.45%
Operating Cash Flow Q/Q Growth	0.00%	-259.65%	2.94%	-16.36%	127.35%	-55.01%	-0.89%	-5.83%	6.22%	24.38%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-22.04%	67.38%	-25.66%	-6.88%	-7.39%	-10.60%	32.57%
Invested Capital Q/Q Growth	0.00%	0.00%	29.13%	11.88%	88.51%	-15.03%	-42.83%	136.68%	1,655.34%	604.06%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-10,358.70%	218.96%	-150.79%	-5,013.89%	26.76%	-47,131.02%	43.44%	-52,281.14%	-35.26%	-920.31%
Operating Margin	-10,416.60%	-1,319.33%	-157.69%	-5,087.80%	16.14%	-49,295.55%	40.82%	-56,190.40%	-59.95%	-1,250.38%
EBIT Margin	-10,410.12%	201.05%	-158.17%	-5,126.54%	25.13%	-48,408.34%	41.48%	-54,298.83%	-40.60%	-971.93%
Profit (Net Income) Margin	-10,456.68%	-449.30%	-166.74%	-5,281.08%	23.09%	-48,520.86%	41.28%	-54,271.70%	-41.38%	-981.54%
Tax Burden Percent	100.03%	102.13%	102.63%	100.34%	99.33%	100.23%	99.51%	99.95%	101.92%	100.99%
Interest Burden Percent	100.42%	-218.82%	102.72%	102.67%	92.49%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.67%	0.00%	0.49%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3,444.29%	-160.45%	-303.26%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3,435.86%	-160.58%	-301.05%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3,413.87%	152.28%	284.06%
Return on Equity (ROE)	-72.97%	-17.30%	-32.50%	-56.89%	10.04%	-26.80%	18.59%	-30.42%	-8.17%	-19.20%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,599.81%	-3,347.07%	-345.97%	-155.73%
Operating Return on Assets (OROA)	-16.13%	4.12%	-21.04%	-42.13%	9.36%	-24.05%	16.57%	-26.05%	-6.74%	-16.22%
Return on Assets (ROA)	-16.20%	-9.20%	-22.18%	-43.40%	8.59%	-24.10%	16.49%	-26.03%	-6.87%	-16.38%
Return on Common Equity (ROCE)	59.98%	-13.14%	-32.50%	-56.89%	10.04%	-26.80%	18.59%	-30.42%	-8.17%	-19.20%
Return on Equity Simple (ROE_SIMPLE)	88.77%	-9.96%	-36.39%	-42.07%	7.12%	-20.96%	15.74%	-34.67%	-8.16%	-18.96%
Net Operating Profit after Tax (NOPAT)	-18	-48	-45	-111	46	-248	372	-471	-156	-327
NOPAT Margin	-7,291.62%	-923.53%	-110.38%	-3,561.46%	16.03%	-34,506.88%	40.62%	-39,333.28%	-41.97%	-875.26%
Net Nonoperating Expense Percent (NNEP)	-13.21%	11.21%	-8.23%	-15.36%	2.92%	-7.65%	0.29%	-8.43%	0.12%	-2.20%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-25.12%	-8.27%	-16.90%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	5,426.32%	601.39%	87.43%	1,545.90%	21.92%	11,925.87%	10.90%	8,552.92%	20.52%	195.58%
R&D to Revenue	5,090.28%	817.93%	170.26%	3,641.90%	61.94%	30,790.26%	37.22%	38,534.64%	104.34%	859.34%
Operating Expenses to Revenue	10,516.60%	1,419.33%	257.69%	5,187.80%	83.86%	49,395.55%	59.18%	56,290.40%	159.95%	1,350.38%
Earnings before Interest and Taxes (EBIT)	-26	10	-65	-160	73	-348	380	-651	-151	-363
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-26	11	-62	-157	77	-339	397	-626	-131	-343
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	3.46	5.13	3.78	3.58	6.50	2.42	1.70	2.64	1.74
Price to Tangible Book Value (P/TBV)	0.00	3.47	5.14	3.78	3.58	6.50	2.42	1.70	2.64	1.74
Price to Revenue (P/Rev)	0.00	156.18	23.49	474.62	11.61	15,045.33	6.34	2,656.64	13.40	90.03
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	50.28	0.00	15.56	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	1.99%	0.00%	6.43%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	168.22	186.92	17.51	51.52
Enterprise Value to Revenue (EV/Rev)	0.00	95.08	17.64	328.44	8.35	12,694.38	3.74	1,097.00	8.83	39.01
Enterprise Value to EBITDA (EV/EBITDA)	0.00	43.43	0.00	0.00	31.21	0.00	8.60	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	47.29	0.00	0.00	33.23	0.00	9.01	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	52.09	0.00	9.20	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	42.67	0.00	6.35	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	10.52	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	1.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-3.34	-1.63	-1.33	-1.21	-1.05	-1.01	-1.00	-0.99	-0.95	-0.94
Leverage Ratio	4.50	1.88	1.47	1.31	1.17	1.11	1.13	1.17	1.19	1.17
Compound Leverage Factor	4.52	-4.11	1.50	1.35	1.08	1.11	1.13	1.17	1.19	1.17
Debt to Total Capital	51.99%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	51.99%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	87.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-39.46%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-1.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	4.60	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-1.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-2.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	6.53	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-2.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	5.24	6.67	8.36	17.09	39.64	11.56	4.64	8.89	6.12
Noncontrolling Interest Sharing Ratio	182.20%	24.04%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	15.44	14.56	17.12	16.81	17.29	18.21	20.17	15.30	17.54	22.07
Quick Ratio	15.39	14.49	16.70	16.46	16.53	17.93	19.85	14.99	17.41	21.97
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	65	-45	-76	-102	-14	-226	325	-458	-336	-168
Operating Cash Flow to CapEx	5,149.74%	-1,752.65%	-897.02%	-3,470.57%	847.95%	-1,298.43%	659.66%	-1,333.07%	-2,749.47%	-7,510.47%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.02	0.13	0.01	0.37	0.00	0.40	0.00	0.17	0.02
Accounts Receivable Turnover	0.73	2.95	14.18	2.30	3,097.22	5.92	4,075.56	0.00	0.00	0.33
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.19	0.46	2.06	0.17	11.62	0.02	10.18	0.01	2.35	0.26
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	500.95	123.55	25.74	158.55	0.12	61.68	0.09	0.00	0.00	1,100.46
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	500.95	123.55	25.74	158.55	0.12	61.68	0.09	0.00	0.00	1,100.46
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-83	-86	-55	-64	-4.35	-26	20	7.03	187	28
Invested Capital Turnover	-0.01	-0.06	-0.58	-0.05	-8.42	-0.05	-317.25	0.09	3.82	0.35
Increase / (Decrease) in Invested Capital	-83	-2.90	31	-9.37	60	-22	46	-13	180	-159
Enterprise Value (EV)	0.00	491	723	1,026	2,418	9,127	3,420	1,314	3,277	1,456
Market Capitalization	0.00	807	963	1,483	3,362	10,818	5,799	3,183	4,972	3,360
Book Value per Share	($5.78)	$5.85	$4.58	$7.56	$17.02	$23.56	$31.35	$23.95	$23.70	$22.64
Tangible Book Value per Share	($5.87)	$5.84	$4.57	$7.55	$17.01	$23.55	$31.35	$23.95	$23.70	$22.64
Total Capital	74	233	188	392	939	1,664	2,399	1,875	1,883	1,932
Total Debt	38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-118	-316	-240	-457	-944	-1,690	-2,379	-1,868	-1,696	-1,904
Capital Expenditures (CapEx)	1.15	3.02	7.81	2.77	6.68	18	82	37	9.47	1.90
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-9.28	-17	-5.88	-18	-13	-68	-81	-83	106	-54
Debt-free Net Working Capital (DFNWC)	147	298	234	439	930	1,622	2,298	1,732	1,799	1,849
Net Working Capital (NWC)	147	298	234	439	930	1,622	2,298	1,732	1,799	1,849
Net Nonoperating Expense (NNE)	7.82	-24	23	54	-20	101	-5.97	179	-2.17	40
Net Nonoperating Obligations (NNO)	-118	-319	-243	-457	-944	-1,690	-2,379	-1,868	-1,696	-1,904
Total Depreciation and Amortization (D&A)	0.13	0.93	3.02	3.52	4.73	9.18	18	24	20	19
Debt-free, Cash-free Net Working Capital to Revenue	-3,755.47%	-335.59%	-14.35%	-576.18%	-4.60%	-9,453.69%	-8.91%	-6,961.52%	28.45%	-145.99%
Debt-free Net Working Capital to Revenue	59,386.64%	5,774.40%	570.47%	14,041.26%	321.30%	225,641.31%	251.12%	144,567.53%	484.71%	4,956.18%
Net Working Capital to Revenue	59,386.64%	5,774.40%	570.47%	14,041.26%	321.30%	225,641.31%	251.12%	144,567.53%	484.71%	4,956.18%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($5.06)	($1.89)	($1.71)	($3.44)	$1.23	($5.29)	$4.97	($8.36)	($1.94)	($4.34)
Adjusted Weighted Average Basic Shares Outstanding	5.04M	39.81M	46.98M	52.28M	54.39M	65.95M	75.95M	77.75M	79.22M	84.36M
Adjusted Diluted Earnings per Share	($5.06)	($1.89)	($1.71)	($3.44)	$1.17	($5.29)	$4.70	($8.36)	($1.94)	($4.34)
Adjusted Weighted Average Diluted Shares Outstanding	5.04M	39.81M	46.98M	52.28M	56.93M	65.95M	80.39M	77.75M	79.22M	84.36M
Adjusted Basic & Diluted Earnings per Share	($5.06)	($1.89)	($1.71)	($3.44)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.04M	12.26M	40.06M	47.96M	60.85M	75.43M	77.07M	78.65M	80.28M	85.77M
Normalized Net Operating Profit after Tax (NOPAT)	-18	-48	-45	-111	46	-248	372	-471	-156	-327
Normalized NOPAT Margin	-7,291.62%	-923.53%	-110.38%	-3,561.46%	16.03%	-34,506.88%	40.62%	-39,333.28%	-41.97%	-875.26%
Pre Tax Income Margin	-10,453.85%	-439.93%	-162.47%	-5,263.38%	23.24%	-48,408.34%	41.48%	-54,298.83%	-40.60%	-971.93%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-1.43%	-7.80%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from CRISPR Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-88.59%	-99.95%	10,538.30%	44,203.80%	-100.00%	3,353,333.33%	-99.50%	-99.26%	0.00%	-82.26%
EBITDA Growth	-38.95%	16.78%	72.46%	58.33%	37.21%	182.73%	-137.79%	-67.38%	24.80%	-133.63%
EBIT Growth	-37.09%	16.34%	70.53%	57.26%	36.19%	174.62%	-123.92%	-62.88%	23.87%	-140.87%
NOPAT Growth	-41.55%	9.72%	63.35%	48.04%	27.40%	175.37%	-118.01%	-58.85%	16.83%	-165.15%
Net Income Growth	-37.27%	21.72%	70.39%	58.17%	35.75%	180.80%	-119.71%	-62.60%	23.37%	-141.76%
EPS Growth	-34.13%	10.26%	71.12%	59.17%	37.05%	180.00%	-113.43%	-52.04%	28.37%	-136.61%
Operating Cash Flow Growth	-29.37%	-31.72%	106.51%	6.14%	62.12%	15.23%	1,147.32%	28.27%	-168.25%	47.92%
Free Cash Flow Firm Growth	50.86%	46.92%	108.88%	29.35%	-36.86%	-40.53%	-930.14%	66.55%	6.70%	202.68%
Invested Capital Growth	-153.90%	-65.42%	-246.24%	151.60%	37.23%	2,561.61%	30.08%	-174.11%	133.35%	-84.90%
Revenue Q/Q Growth	-40.51%	-93.62%	1,666,566.67%	-30.00%	-100.00%	0.00%	-99.75%	2.58%	16.44%	5,828.74%
EBITDA Q/Q Growth	1.36%	32.86%	59.11%	-53.89%	-48.65%	188.45%	-217.52%	-8.32%	33.21%	60.45%
EBIT Q/Q Growth	2.56%	31.45%	56.90%	-48.45%	-45.46%	180.17%	-229.34%	-7.99%	32.01%	56.96%
NOPAT Q/Q Growth	0.48%	27.88%	50.98%	-47.66%	-39.05%	174.88%	-241.80%	-7.59%	27.19%	41.35%
Net Income Q/Q Growth	6.07%	36.65%	52.01%	-46.50%	-44.27%	179.67%	-230.49%	-8.42%	32.01%	56.59%
EPS Q/Q Growth	6.67%	37.50%	52.14%	-46.27%	-43.88%	179.43%	-227.68%	-4.20%	32.21%	59.41%
Operating Cash Flow Q/Q Growth	25.88%	-7.71%	107.76%	-1,614.32%	70.09%	-141.05%	214.24%	-187.09%	-11.85%	53.20%
Free Cash Flow Firm Q/Q Growth	44.33%	-8.00%	116.64%	-806.28%	-7.82%	-10.90%	1.71%	71.54%	-200.71%	222.05%
Invested Capital Q/Q Growth	-212.09%	136.68%	-592.02%	224.37%	-127.97%	1,655.34%	-112.93%	-31.82%	112.59%	604.06%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-180,963.83%	-1,903,416.67%	-46.69%	-102.65%	0.00%	46.96%	-22,030.56%	-23,264.22%	-13,343.36%	-89.01%
Operating Margin	-194,029.79%	-2,192,350.00%	-64.49%	-136.03%	0.00%	34.58%	-27,894.25%	-29,257.25%	-18,294.02%	-180.97%
EBIT Margin	-186,302.13%	-2,000,850.00%	-51.75%	-109.74%	0.00%	44.52%	-22,989.48%	-24,201.35%	-14,130.56%	-102.58%
Profit (Net Income) Margin	-185,690.43%	-1,842,916.67%	-53.07%	-111.06%	0.00%	44.41%	-23,133.13%	-24,450.29%	-14,276.08%	-104.54%
Tax Burden Percent	99.67%	92.11%	102.55%	101.20%	100.37%	99.74%	100.62%	101.03%	101.03%	101.91%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.26%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-233,467.72%	-134,383.80%	0.00%	-538.80%	0.00%	131.89%	0.00%	-743,692.69%	0.00%	-43.89%
ROIC Less NNEP Spread (ROIC-NNEP)	-233,465.61%	-134,382.92%	0.00%	-538.22%	0.00%	130.77%	0.00%	-743,691.61%	0.00%	-44.33%
Return on Net Nonoperating Assets (RNNOA)	232,608.71%	133,522.80%	0.00%	529.94%	0.00%	-124.01%	0.00%	741,510.07%	0.00%	41.83%
Return on Equity (ROE)	-859.01%	-861.00%	-25.56%	-8.86%	-19.20%	7.88%	-11.03%	-2,182.62%	-13.07%	-2.06%
Cash Return on Invested Capital (CROIC)	0.00%	-3,347.07%	0.00%	-1,189.11%	0.00%	-345.97%	0.00%	0.00%	-6,197.88%	-155.73%
Operating Return on Assets (OROA)	-1,014.55%	-959.78%	-2.14%	-8.01%	0.00%	7.39%	-2,667.51%	-2,157.51%	-1,319.88%	-1.71%
Return on Assets (ROA)	-1,011.22%	-884.02%	-2.19%	-8.11%	0.00%	7.37%	-2,684.17%	-2,179.70%	-1,333.47%	-1.74%
Return on Common Equity (ROCE)	-859.01%	-861.00%	-25.56%	-8.86%	-19.20%	7.88%	-11.03%	-2,182.62%	-13.07%	-2.06%
Return on Equity Simple (ROE_SIMPLE)	-34.84%	0.00%	-28.25%	-22.90%	-20.46%	0.00%	-10.42%	-13.42%	-12.35%	0.00%
Net Operating Profit after Tax (NOPAT)	-128	-92	-45	-67	-93	69	-98	-106	-77	-45
NOPAT Margin	-135,820.85%	-1,534,645.00%	-45.14%	-95.22%	0.00%	34.49%	-19,525.97%	-20,480.08%	-12,805.81%	-126.68%
Net Nonoperating Expense Percent (NNEP)	-2.11%	-0.87%	-0.39%	-0.58%	-1.05%	1.12%	-0.91%	-1.08%	-0.48%	0.44%
Return On Investment Capital (ROIC_SIMPLE)	-	-4.91%	-	-	-	3.69%	-	-	-	-2.34%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	28,724.47%	352,816.67%	22.36%	27.19%	0.00%	8.19%	3,562.10%	3,768.09%	2,893.52%	50.78%
R&D to Revenue	124,065.96%	1,725,916.67%	99.94%	145.08%	0.00%	47.29%	15,113.49%	15,505.80%	13,647.84%	230.19%
Operating Expenses to Revenue	194,129.79%	2,192,450.00%	164.49%	236.03%	0.00%	65.42%	27,994.25%	29,357.25%	18,394.02%	280.97%
Earnings before Interest and Taxes (EBIT)	-175	-120	-52	-77	-112	90	-116	-125	-85	-37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-170	-114	-47	-72	-107	94	-111	-120	-80	-32
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.61	1.70	1.92	2.44	2.09	2.64	2.60	2.32	2.06	1.74
Price to Tangible Book Value (P/TBV)	2.61	1.70	1.92	2.44	2.09	2.64	2.60	2.32	2.06	1.74
Price to Revenue (P/Rev)	361.78	2,656.64	35.48	26.05	21.20	13.40	19.93	22.68	19.73	90.03
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	186.92	0.00	61.79	0.00	17.51	0.00	0.00	514.72	51.52
Enterprise Value to Revenue (EV/Rev)	221.76	1,097.00	16.63	15.63	10.97	8.83	12.17	12.73	10.18	39.01
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.00	-0.99	-1.00	-0.98	-1.01	-0.95	-1.01	-1.00	-1.00	-0.94
Leverage Ratio	1.16	1.17	1.18	1.19	1.21	1.19	1.19	1.19	1.18	1.17
Compound Leverage Factor	1.16	1.17	1.18	1.19	1.21	1.19	1.19	1.19	1.18	1.17
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	7.89	5.42	5.83	7.26	6.15	9.24	9.45	7.80	7.71	6.60
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	12.81	15.30	13.00	14.00	15.83	17.54	17.81	15.73	21.64	22.07
Quick Ratio	12.57	14.99	12.83	13.84	15.64	17.41	17.72	15.66	21.55	21.97
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-73	-79	13	-93	-100	-111	-109	-31	-93	114
Operating Cash Flow to CapEx	-1,748.68%	-1,830.53%	287.64%	-3,748.10%	-1,881.78%	-13,018.02%	15,222.19%	-13,519.38%	-48,818.72%	-19,697.24%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.01	0.00	0.04	0.07	0.08	0.17	0.12	0.09	0.09	0.02
Accounts Receivable Turnover	140.21	0.00	0.00	4.86	0.00	0.00	0.00	0.00	0.00	0.33
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.10	0.01	0.63	1.05	1.06	2.35	1.76	1.34	1.38	0.26
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	2.60	0.00	0.00	75.17	0.00	0.00	0.00	0.00	0.00	1,100.46
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	2.60	0.00	0.00	75.17	0.00	0.00	0.00	0.00	0.00	1,100.46
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-19	7.03	-35	43	-12	187	-24	-32	4.01	28
Invested Capital Turnover	1.72	0.09	-18.33	5.66	-10.90	3.82	-9.24	36.31	-50.59	0.35
Increase / (Decrease) in Invested Capital	-55	-13	-58	26	7.14	180	10	-75	16	-159
Enterprise Value (EV)	3,125	1,314	1,668	2,658	1,865	3,277	3,306	2,574	2,066	1,456
Market Capitalization	5,098	3,183	3,557	4,431	3,604	4,972	5,414	4,586	4,001	3,360
Book Value per Share	$25.05	$23.95	$23.59	$23.01	$21.76	$23.70	$25.48	$23.33	$22.77	$22.64
Tangible Book Value per Share	$25.05	$23.95	$23.58	$23.01	$21.76	$23.70	$25.48	$23.33	$22.77	$22.64
Total Capital	1,954	1,875	1,855	1,816	1,728	1,883	2,084	1,981	1,940	1,932
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,973	-1,868	-1,889	-1,773	-1,740	-1,696	-2,108	-2,013	-1,936	-1,904
Capital Expenditures (CapEx)	6.02	6.19	3.06	3.56	2.12	0.74	0.72	0.71	0.22	0.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-114	-83	-122	-41	-90	106	-107	-119	-82	-54
Debt-free Net Working Capital (DFNWC)	1,782	1,732	1,761	1,727	1,649	1,799	2,001	1,883	1,854	1,849
Net Working Capital (NWC)	1,782	1,732	1,761	1,727	1,649	1,799	2,001	1,883	1,854	1,849
Net Nonoperating Expense (NNE)	47	18	7.92	11	19	-20	18	21	8.85	-7.90
Net Nonoperating Obligations (NNO)	-1,973	-1,868	-1,889	-1,773	-1,740	-1,696	-2,108	-2,013	-1,936	-1,904
Total Depreciation and Amortization (D&A)	5.02	5.85	5.05	4.96	4.93	4.90	4.83	4.85	4.74	4.84
Debt-free, Cash-free Net Working Capital to Revenue	-810.03%	-6,961.52%	-121.68%	-24.32%	-53.22%	28.45%	-39.56%	-58.86%	-40.21%	-145.99%
Debt-free Net Working Capital to Revenue	12,645.18%	144,567.53%	1,756.64%	1,015.13%	970.17%	484.71%	736.31%	930.93%	914.11%	4,956.18%
Net Working Capital to Revenue	12,645.18%	144,567.53%	1,756.64%	1,015.13%	970.17%	484.71%	736.31%	930.93%	914.11%	4,956.18%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.24)	($1.40)	($0.67)	($0.98)	($1.41)	$1.12	($1.43)	($1.49)	($1.01)	($0.41)
Adjusted Weighted Average Basic Shares Outstanding	78.02M	77.75M	78.68M	79.09M	79.41M	79.22M	81.79M	84.92M	85.23M	84.36M
Adjusted Diluted Earnings per Share	($2.24)	($1.40)	($0.67)	($0.98)	($1.41)	$1.12	($1.43)	($1.49)	($1.01)	($0.41)
Adjusted Weighted Average Diluted Shares Outstanding	78.02M	77.75M	78.68M	79.09M	79.41M	79.22M	81.79M	84.92M	85.23M	84.36M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	78.29M	78.65M	78.94M	79.41M	79.43M	80.28M	84.92M	85.17M	85.35M	85.77M
Normalized Net Operating Profit after Tax (NOPAT)	-128	-92	-45	-67	-93	69	-98	-106	-77	-45
Normalized NOPAT Margin	-135,820.85%	-1,534,645.00%	-45.14%	-95.22%	0.00%	34.49%	-19,525.97%	-20,480.08%	-12,805.81%	-126.68%
Pre Tax Income Margin	-186,302.13%	-2,000,850.00%	-51.75%	-109.74%	0.00%	44.52%	-22,989.48%	-24,201.35%	-14,130.56%	-102.58%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About CRISPR Therapeutics' Financials

When does CRISPR Therapeutics's fiscal year end?

According to the most recent income statement we have on file, CRISPR Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has CRISPR Therapeutics' net income changed over the last 9 years?

CRISPR Therapeutics' net income appears to be on an upward trend, with a most recent value of -$366.25 million in 2024, rising from -$25.83 million in 2015. The previous period was -$153.61 million in 2023.

What is CRISPR Therapeutics's operating income?

CRISPR Therapeutics's total operating income in 2024 was -$466.57 million, based on the following breakdown:

Total Gross Profit: $37.31 million
Total Operating Expenses: $503.88 million

How has CRISPR Therapeutics revenue changed over the last 9 years?

Over the last 9 years, CRISPR Therapeutics' total revenue changed from $247 thousand in 2015 to $37.31 million in 2024, a change of 15,006.9%.

How much debt does CRISPR Therapeutics have?

CRISPR Therapeutics' total liabilities were at $309.95 million at the end of 2024, a 10.6% decrease from 2023, and a 149.9% increase since 2015.

How much cash does CRISPR Therapeutics have?

In the past 9 years, CRISPR Therapeutics' cash and equivalents has ranged from $155.96 million in 2015 to $1.17 billion in 2020, and is currently $298.26 million as of their latest financial filing in 2024.

How has CRISPR Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, CRISPR Therapeutics' book value per share changed from -5.78 in 2015 to 22.64 in 2024, a change of -491.9%.

Remove Ads

Related Companies

This page (NASDAQ:CRSP) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CRISPR Therapeutics (CRSP) Financials

Frequently Asked Questions About CRISPR Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CRISPR Therapeutics (CRSP) Financials

Annual Income Statements for CRISPR Therapeutics

Quarterly Income Statements for CRISPR Therapeutics

Annual Cash Flow Statements for CRISPR Therapeutics

Quarterly Cash Flow Statements for CRISPR Therapeutics

Annual Balance Sheets for CRISPR Therapeutics

Quarterly Balance Sheets for CRISPR Therapeutics

Annual Metrics and Ratios for CRISPR Therapeutics

Quarterly Metrics and Ratios for CRISPR Therapeutics

Frequently Asked Questions About CRISPR Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools